GlassScriptPhysician profile
Douglas F Mcmahon
NPI 1356533293
$17,751.80
in general payments reported to CMS, 2019-2025
19 companies · $4,193 in 2025
The $4,193 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $12K · 2021: $40.42 · 2022: $68.84 · 2023: $1,533 · 2024: $107 · 2025: $4,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,449 · Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,449.00 |
| Food and Beverage | $384.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $10,259.24 | 2020 | |
| Incyte Corporation | $3,967.95 | 2024-2025 | Opzelura |
| Genentech USA, INC. | $1,517.43 | 2023-2024 | Xolair |
| Astrazeneca Pharmaceuticals LP | $1,435.13 | 2019-2025 | Airsupra |
| Alk-Abello, INC | $130.87 | 2019 | |
| Kyowa Kirin, INC. | $108.06 | 2025 | |
| Pharming Healthcare, INC. | $63.06 | 2022-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $55.06 | 2019-2025 | Dupixent |
| Phadia US INC. | $53.53 | 2020-2025 | Immunocap |
| Amgen INC. | $34.17 | 2023-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $26.63 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.04 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $15.24 | 2025 | |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Genzyme Corporation | $14.62 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $14.00 | 2022 | |
| Glaxosmithkline, LLC. | $13.96 | 2025 | Nucala |
| Philips North America LLC | $11.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.